drugset / Trial / NCT04800874
Study of BBP-418 in Patients With LGMD2I
Non-randomizedSequentialOpen-labelTreatment
Summary
BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is an open label study to determine the safety and tolerability of ascending dose levels of BBP-418 in the treatment of ambulatory and non-ambulatory patients with LGMD2I for which no approved therapy currently exists.
Timeline
- Start
- 2021-02-18
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ribitol | Small molecule | 12 g | — |